Emend Injection Side Effects

Please note - some side effects for Emend Injection may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects by Body System - for Healthcare Professionals

Applies to: intravenous powder for injection

General

In general, because fosaprepitant injection is converted to aprepitant, those adverse experiences associated with aprepitant might also be expected to occur with fosaprepitant for injection. General side effects including asthenia/fatigue (17.8%), dizziness (3.4% to 6.6%), dehydration (5.9%), abdominal pain (4.6%), fever (2.9%), mucous membrane disorder (2.6%) have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Diaphoresis, edema, flushing, malaise, pelvic pain, septic shock, and upper respiratory infection have also been reported.

Local

Local side effects reported with the use of fosaprepitant injection have included infusion site pain (7.6%) and infusion site induration (1.5%).

Nervous system

Nervous system side effects including headache (2.3%) have been reported with the use of fosaprepitant injection. Nervous system side effects including headache (8.5% to 16.4%) and insomnia (2.9%) have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy. Peripheral neuropathy and sensory neuropathy have also been reported.

Dermatologic

Dermatologic side effects including alopecia (24%) and rash have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy.

Gastrointestinal

Gastrointestinal side effects including nausea (7.1% to 12.7%), constipation (10.3% to 12.3%), diarrhea (5.5% to 10.3%), dyspepsia (8.4%), vomiting (7.5%), stomatitis (5.3%), heartburn (5.3%), gastritis (4.2%), and epigastric discomfort (4.0%) have been reported with the use of aprepitant as a part of a regimen with ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Acid reflux, deglutination, disorder, dysgeusia, dysphagia, flatulence, obstipation, increased salivation, and taste disturbance have also been reported.

Respiratory

Respiratory side effects including hiccups (10.8%) have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy. Cough, dyspnea, pneumonitis, respiratory insufficiency, lower respiratory infection, nasal secretion, pharyngitis, pharyngolaryngeal pain, and vocal disturbance have also been reported.

Other

Other side effects including anorexia (4.3% to 10.1%) and tinnitus (3.7%) have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with moderately or highly emetogenic cancer chemotherapy.

Oncologic

Thyroid follicular cell adenomas and carcinomas in male rats and increased incidences of hepatocellular adenoma and thyroid follicular adenoma in female rats have been reported. Aprepitant has also been reported to cause skin fibrosarcomas in male mice.

Oncologic side effects including malignant neoplasm and non-small cell lung carcinoma have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Hematologic

Hematologic side effects including neutropenia have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy. Anemia, febrile neutropenia, and thrombocytopenia have also been reported.

Cardiovascular

Cardiovascular side effects including deep vein thrombosis, hypertension, hypotension, myocardial infarction, pulmonary embolism, and tachycardia have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Metabolic

Metabolic side effects including diabetes mellitus have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy. Decreased appetite, hypokalemia, and weight loss have also been reported.

Musculoskeletal

Musculoskeletal side effects including muscular weakness, musculoskeletal pain, and myalgia have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Psychiatric

Psychiatric side effects including anxiety disorder, confusion, and depression have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Genitourinary

Genitourinary side effects including dysuria and renal insufficiency have been reported with the use of aprepitant as a part of a regimen that also included ondansetron and dexamethasone which was given along with highly emetogenic cancer chemotherapy.

Hypersensitivity

Hypersensitivity side effects have included immediate flushing, erythema, and dyspnea during infusion of fosaprepitant. These hypersensitivity reactions have generally responded to discontinuation of the infusion and administration of appropriate therapy. It is not recommended to reinitiate the infusion in patients who experience hypersensitivity reactions.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.